Characterization of Nevirapine Resistance Mutations in Women with Subtype A Vs. D HIV-1 6-8 Weeks after Single-Dose Nevirapine (HIVNET 012)

Journal of Acquired Immune Deficiency Syndromes

Volumn 35, Issue 2, 2004, Pages 126-130

  Eshleman, Susan H ^a   Guay, Laura A ^a   Mwatha, Anthony ^b   Brown, Elizabeth R ^c   Cunningham, Shawn P ^a   Musoke, Philippa ^d   Mmiro, Francis ^d   Jackson, J Brooks ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d MAKERERE UNIVERSITY   (Uganda)

Author keywords

Drug resistance; HIV 1; Nevirapine; Subtype; Uganda

Indexed keywords

NEVIRAPINE;

ARTICLE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; PROPHYLAXIS; SINGLE DRUG DOSE; STRUCTURAL GENE; UGANDA; VIRUS LOAD; VIRUS MUTATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV-1; HUMANS; MUTATION, MISSENSE; NEVIRAPINE; PHYLOGENY; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 1642499255     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200402010-00004     Document Type: Article

References (21)

1. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-infant transmission of HIV-1 in Kampala, Uganda: HIVNET-012 randomised trial. Lancet. 1999;354:795-802.
2. Owor M, Deseyve M, Duefield C, et al. The one year safety and efficacy data of the HIVNET 012 trial. Paper presented at: XIII International AIDS Conference; July 9-14, 2002; Durban, South Africa.
3. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18 months follow-up of the HIVNET 012 randomised trial. Lancet. 2003;362:859-868.
4. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 2001;15:1951-1957.
5. Eshleman SH, Becker-Pergola G, Deseyve M, et al. Impact of HIV-1 subtype on women receiving single dose NVP prophylaxis to prevent HIV-1 vertical transmission (HIVNET 012). J Infect Dis. 2001;184:914-917.
6. Kantor R, Katzenstein D, Camacho R, et al. Genotypic analyses of RT and protease sequences from persons infected with non-subtype B HIV-1. Paper presented at: 10th Conference on Retroviruses and Opportunistic Infections, Feb 12-14, 2003; Boston, MA.
7. Caride E, Hertogs K, Larder B, et al. Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in Brazilian patients failing HAART. Virus Genes. 2001;23:193-202.
8. Tanuri A, Soares MA, Dumans AT, et al. Synonymous genetic changes within subtype F may influence mutational routes to drug resistance. Antivir Ther. 2003;8:S142.
9. Kantor R, Carvalho AP, Wynhoven B, et al. Nucleic acid differences between HIV-1 non-B and B reverse transcriptase and protease sequences at drug resistance positions. Antivir Ther. 2003;8:S58.
10. Turner D, Brenner B, Spira B, et al. Novel drug resistance profiles in non-B subtype HIV-1 infections. Paper presented at: 10th Conference on Retroviruses and Opportunistic Infections; Feb 12-14, 2003; Boston, MA.
11. Abecasis A, Gomes P, Derdelinckx I, et al. L891/V: a novel mutation selected by protease inhibitor therapy in subtype G, but not in subtype B-infected patients. Antivir Ther. 2003;8:S140.
12. Siepel AC, Halpern AL, Macken C, et al. A computer program designed to screen rapidly for HIV type 1 intersubtype recombinant sequences. AIDS Res Hum Retroviruses. 1995;11:1413-1416.
13. Shafer RW, Dupnik K, Winters MA, et al. A guide to HIV-1 reverse transcriptase and protease sequencing for drug resistance studies. Human Retroviruses and AIDS 2001: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Available at: http://hiv-web.lanl.gov/. Los Alamos, NM: Los Alamos National Laboratory; 2001. (accessed 12/03).
14. Eshleman SH, Gonzales MJ, Becker-Pergola G, et al. Identification of Ugandan HIV-1 variants with unique patterns of recombination in pol involving subtypes A and D. AIDS Res Hum Retroviruses. 2002;18:507-511.
15. Page RD. TreeView: an application to display phylogenetic trees on personal computers. Comput Appl Biosci. 1996;12:357-358.
16. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. JAMA. 1998;279:1984-1991.
17. Havlir DV, Eastman S, Gamst A, et al. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol. 1996;70:7894-7899.
18. Eshleman SH, Jones D, Guay L, et al. HIV-1 variants with diverse nevirapine resistance mutations emerge rapidly after single-dose nevirapine: HIVNET 012. Antivir Ther. 2003;8:S86.
19. Eshleman SH, Guay LA, Mwatha A, et al. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single dose NVP prophylaxis: HIVNET 012. AIDS Res Hum Retroviruses. (in press).
20. Kantor R, Lee E, Johnston E, et al. Rapid flux in non-nucleoside reverse transcriptase mutations among subtype C HIV-1-infected women after single dose nevirapine. Antivir Ther. 2003;8:S85.
21. Cunningham CK, Chaix M-L, Rekacewicz C, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of Pediatric AIDS Clinical Trials Group Protocol 316. J Infect Dis. 2002;186:181-188.